A practical reference on PPARδ agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Contaminants of emerging concern (CEC) is a term used by water quality professionals to describe pollutants that have been detected in environmental monitoring samples, that may cause ecological or human health impacts, and typically are not regulated under current environmental laws. Sources of these pollutants include agriculture, urban runoff and ordinary household products (such as soaps and disinfectants) and pharmaceuticals that are disposed to sewage treatment plants and subsequently discharged to surface waters. CEC include different substances like pharmaceuticals, personal care products, industrial byproducts, and agricultural chemicals. These substances often bypass regular detection and treatment processes, leading to their unintended persistence in the environment. The complexity of CEC arises not only from their different chemical nature but also from the complex ways they interact with ecosystems and human health. As such, they are the focus of increasing examination by researchers, policymakers, and public health officials who want to understand their long-term effects and develop effective interventions. Global initiatives, like those from the World Health Organization (WHO) and the United States Environmental Protection Agency (US EPA), emphasize the need to create international standards and effective environmental policies to address the challenges posed by CEC.
== Side effects == Side effects are similar to other prostaglandin analogs applied to the eye. The most common one is conjunctival hyperemia, which occurs in more than 10% of patients. Other effects include blurred vision, eye and eyelid redness, eye burning or other discomfort, and permanent darkening of the iris to brown. Occasional adverse effects (in less than 1% of patients) are headache and nausea. Some side effects are specific to the cosmetic formulation, which is applied to the skin at the base of the eyelash rather than instilled into the eye. These include infection if the one-time applicators are reused, and darkening of the eyelid or of the area beneath the eye. Research suggests that wiping the eye with an absorbent pad after the administration of eye drops can result in shorter eyelashes and a lesser chance of hyperpigmentation in the eyelid, compared to not wiping off excess fluid.
== Medical uses == An intravenous infusion of oxytocin is used to induce labor and to support labor in case of slow childbirth if the oxytocin challenge test fails. The physiology of labor stimulated by oxytocin administration is similar to the physiology of spontaneous labor. It is associated with less tachysystole (more than five contractions in 10 minutes, averaged over a 30-minute period, which can but does not always cause fetal distress) than other induction methods and allows achievement of delivery with amniotomy to proceed faster. Whether a high dose is better than a standard dose for labor induction is unclear. It has largely replaced ergometrine as the principal agent to increase uterine tone in acute postpartum hemorrhage. Oxytocin is also used in veterinary medicine to facilitate birth and to stimulate milk release. The tocolytic agent atosiban (Tractocile) acts as an antagonist of oxytocin receptors. It is registered in many countries for use in suppressing premature labor between 24 and 33 weeks of gestation. It has fewer side effects than drugs previously used for this purpose (such as ritodrine, salbutamol and terbutaline). Oxytocin has not been found to be useful for improving breastfeeding success.
histone modification The post-translational modification of histone proteins by the chemical attachment of various molecules or functional groups to specific amino acid residues. Because histones form the core of nucleosomes, the modification of exposed parts of their polypeptide chains is used to regulate gene expression by marking them with molecular labels that signal the recruitment of other proteins to induce conformational changes that variously widen or condense the spacing of nucleosomes along strands of DNA, thereby changing the accessibility of nearby DNA sequences to transcriptional machinery. Histones are modified by many different labels, most commonly methylation, acetylation, ubiquitination, phosphorylation, and citrullination.
The lengthy volume that emerged contained a diverse collection of opinions, with some stating the South Vietnamese were making "rapid strides," while others doubted that the government in Saigon would "ever constitute an effective political or military counter to the Vietcong". The "bulls" estimated that American troops would need to fight on in Vietnam for 8.3 years before the South Vietnamese would be able to fight on their own while the "bears" estimated it would take 13.4 years of American troops fighting in Vietnam before the South Vietnamese would be able to fight on their own. Kissinger passed the volume on to Nixon with the comment that there was no consensus within the expert community with the implied conclusion that he should be free to act on his own without consulting the experts.
Sources: en.wikipedia.org
There is not enough specimen for the lab tests ordered to be performed. In the case of Vacutainers or other tubes with pre-added anticoagulant, the amount of blood invacuated into the tube at the time of phlebotomy was insufficient to attain the correct blood:anticoagulant ratio. This can cause false results in assays such as coagulation assays (causing falsely increased clotting times) or blood cell differentials (causing a false increase in poikilocytes, particularly burr cells.) In either case, the most common and feasible way to correct the problem is to simply recollect the specimen. Quantity not sufficient implies that the final volume of diluent is not sufficient for molecular testing.
=== Advanced planning and techniques === Retrosynthetic analysis is a strategy used to plan complex syntheses by breaking down the target molecule into simpler precursors. Flow chemistry is a continuous reaction method where reactants are pumped through a reactor, allowing precise control over reaction conditions and scalability. This approach has been employed in the large-scale production of pharmaceuticals such as Tamoxifen.
Vilazodone, sold under the brand name Viibryd among others, is a medication used to treat major depressive disorder. It is classified as a serotonin modulator and is taken by mouth. Its common side effects include nausea, diarrhea, and trouble sleeping. Serious side effects may include increased suicidal thoughts or actions in those under the age of 25, serotonin syndrome, bleeding, activation of mania or hypomania, pancreatitis, seizures, angle-closure glaucoma, sleep paralysis, and sexual dysfunction. Vilazodone may cause a syndrome of inappropriate antidiuretic hormone secretion (SIADH). A withdrawal syndrome may occur if the dose is rapidly decreased. Use during pregnancy and breastfeeding is not generally recommended. It is in the serotonin modulator class of medications and is believed to work both as a selective serotonin reuptake inhibitor (SSRI) and activator of the 5-HT1A receptor. Vilazodone was approved for medical use in the United States in 2011 and in Canada in 2018. In 2019, it was the 334th most commonly prescribed medication in the United States, with more than 900 thousand prescriptions. The drug lost patent protection in June 2022 for adults and in July 2023 for pediatrics. Generic versions have been approved by the US Food and Drug Administration.
== References == Aeschliman, M.D (28 March 2005). "Murderous Science". The National Review. Vol. LVII, no. 5. pp. 49–50. Baldwin, Peter (1990). Reworking the Past: Hitler, the Holocaust, and the Historians' Debate. Boston: Beacon Press. Bessel, Richard (August 1990). "Detlev J.K. Peukert". German History. 8 (3): 321–324. doi:10.1093/gh/8.3.321. Crew, David (May 1992). "The Pathologies of Modernity: Detlev Peukert on Germany's Twentieth Century". Social History. 17 (2): 319–328. doi:10.1080/03071029208567840. Kater, Michael (May 1992). "Conflict in Society and Culture: The Challenge of National Socialism". German Studies Review. 15 (2): 289–294. doi:10.2307/1431167. JSTOR 1431167. Kershaw, Ian (2000). The Nazi Dictatorship Problems and Perspectives of Interpretation. London: Arnold Press. ISBN 0-340-76028-1. Lindemann, Albert (February 1982). "Review of Die KPD im Widerstand Verfolgung und Untergrundarbeit am Rhein und Ruhr, 1933-1945". The American Historical Review. 82 (1): 205. doi:10.2307/1863393. JSTOR 1863393. Nolan, Mary (Spring–Summer 1988). "The Historikerstreit and Social History". New German Critique (44): 1–80. Pendas, Devin; Roseman, Mark (2017). Beyond the Racial State: Rethinking Nazi Germany. Cambridge: Cambridge University Press. ISBN 978-1107165458. Peukert, Detlev (1987). Conformity, Opposition and Racism in Everyday Life. New Haven: Yale University Press. ISBN 0300038631. Peukert, Detlev (1994). "The Genesis of the 'Final Solution' from the Spirit of Science". In Thomas Childers; Jane Caplan (eds.). Reevaluating the Third Reich. New York: Holmes & Meier.
==== 2000-2009 ==== In 2000, Teva acquired Canada-based Novopharm. In October 2003, Teva announced its intentions to acquire Sicor Inc. for $3.4 billion. Following the announcement, the acquisition was completed on January 22, 2004, which marked Teva's entry into biosimilars' market. In 2005, Teva opened a new, state-of-the-art pharmaceutical manufacturing plant in Har Hotzvim, a technology park in Jerusalem. The plant received FDA approval in early 2007. Teva entered the Japanese market in 2005 and in 2008 established a generics joint venture with Kowa. In January 2006, Teva acquired its U.S. rival Ivax Corporation for $7.4 billion. In 2008, sales totalled $11.08 billion, $13.9 billion in 2009, and in 2010 total sales rose to $16.1 billion, of which a major portion was in Europe and North America. In July 2008, Teva announced it completed the acquisition of Bentley Pharmaceuticals for its generic pharmaceutical operations in Spain for $360 million in cash. On December 23, 2008, Teva acquired Barr Pharmaceuticals for $7.5 billion, making Barr and Pliva (which Barr bought earlier) part of Teva.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.